|Bid||5.98 x 4000|
|Ask||5.99 x 42300|
|Day's range||5.34 - 6.00|
|52-week range||3.36 - 14.70|
|Beta (5Y monthly)||2.35|
|PE ratio (TTM)||N/A|
|Earnings date||25 Feb 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||10.64|
Image source: The Motley Fool. Amarin (NASDAQ: AMRN)Q4 2020 Earnings CallFeb 25, 2021, 7:30 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorWelcome to Amarin Corporation's conference call to discuss its fourth quarter and full-year 2020 financial results and operational updates.
Amarin's (AMRN) revenue growth in the fourth quarter is attributable to continued demand for its cardiovascular drug, Vascepa.
The drugmaker topped analysts' top- and bottom-line expectations despite challenges from a generic rival and the pandemic.